Phathom Pharmaceuticals, Inc. Retained Earnings

Retained Earnings of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Retained Earnings growth rates and interactive chart.


Highlights and Quick Summary

  • Retained Earnings for the quarter ending September 29, 2021 was $-494 Million (a 8.02% increase compared to previous quarter)
  • Year-over-year quarterly Retained Earnings increased by 28.03%
  • Annual Retained Earnings for 2020 was $-385 Million (a 50.33% increase from previous year)
  • Annual Retained Earnings for 2019 was $-256 Million (a 19808.31% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Retained Earnings of Phathom Pharmaceuticals, Inc.

Most recent Retained Earningsof PHAT including historical data for past 10 years.

Interactive Chart of Retained Earnings of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Retained Earnings for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-493.54 $-456.88 $-420.33
2020 $-385.49 $-331.77 $-297.66 $-276.56 $-385.49
2019 $-256.42 $-158.41 $-256.42
2018 $-1.29 $-1.29

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.